A 52-year-old man struggled with a rare blood condition called chronic myelomonocytic leukemia. This disease often leads to high fever, anemia, and low platelets. Doctors in a hematology department treated him with a combination of azacytidine and ruxolitinib. These drugs target different parts of the cancer process. Before this treatment, he was on a mix of hormones and immunosuppressants. The new plan aimed to stop the disease from growing and fix his blood counts. After two years and ten months, his fever and other body-wide symptoms were significantly relieved. His high white blood cell count returned to normal. His severe anemia and low platelet levels also improved greatly. This single case report shares what happened to this one patient. It is important to remember that this is just one story. We cannot say this works for everyone yet. More research is needed to see if other patients would benefit similarly. Safety was monitored, and no serious side effects were reported during this time. This story shows promise but needs bigger studies to confirm results.
Case report and review: azacytidine plus ruxolitinib in connective tissue disease with CMML and myelofibrosisA single patient found relief from blood cancer with a new drug combo
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Consider that azacytidine plus ruxolitinib may improve symptoms in a single case of connective tissue disease with CMML and myelofibrosis, but evidence is limited.
This is a case report and literature review describing a 52-year-old male patient with connective tissue disease, chronic myelomonocytic leukemia, and myelofibrosis. The patient was treated with a dual-target regimen of azacytidine and ruxolitinib, compared with prior hormone and immunosuppressant combination therapy. The review synthesizes the case findings with existing literature on similar presentations.
The main results from the case report indicate that fever and other systemic symptoms were significantly relieved, monocytosis was corrected, and severe anemia and thrombocytopenia markedly improved. No effect sizes, absolute numbers, p-values, or confidence intervals are reported. The follow-up duration before treatment was 2 years 10 months, but the post-treatment follow-up period is not specified.
Limitations are not explicitly noted by the authors, but as a single case report, the evidence is inherently limited. No adverse events, serious adverse events, or discontinuations are reported. The funding or conflicts of interest are not reported.
Clinicians should interpret these findings with caution. The results are derived from a single patient and cannot be generalized to broader populations. The dual-target regimen may be considered in similar complex cases, but further studies are needed to establish efficacy and safety.
What this means for you:
One patient saw major improvement in blood counts and symptoms with a new drug mix. More on Myelofibrosis
Narrative review proposes phenotype-driven framework for managing myelofibrosis splenomegaly
New combo strategies shrink spleens better than older treatments for myelofibrosis
This narrative review addresses the management of splenomegaly in patients with myelofibrosis. The authors synthesize evidence regarding eme…
Emerging combination strategies like pelabresib plus ruxolitinib or navitoclax plus ruxolitinib show superior spleen shrinkage for myelofibr…
Case report: Low-intensity chemotherapy achieves remission in PMF transformed to MPAL
Single case report describes treatment for rare leukemia transformation in elderly patient
A case report describes a 75-year-old female with JAK2V617F-positive primary myelofibrosis that transformed to mixed phenotype acute leukemi…
A 75-year-old woman with rare leukemia transformation from blood disorder achieved remission after two cycles of low-intensity chemotherapy.
Phase 3 trial of navitoclax plus ruxolitinib versus ruxolitinib alone in myelofibrosis posts results
Phase 3 trial tests navitoclax with ruxolitinib for myelofibrosis spleen volume
A phase 3 randomized controlled trial in 252 adults with myelofibrosis compared navitoclax plus ruxolitinib to ruxolitinib plus placebo.
A new drug combination aims to shrink painful enlarged spleens in myelofibrosis patients, but results from this large global trial are not y…
AZA or LDAC combined with venetoclax likely improves mortality, remission, and quality of life
New combinations show promise for older adults with myeloid leukemia
This systematic review and meta-analysis of 47 studies evaluated treatments for older adults with AML ineligible for conventional chemothera…
Combining specific drugs like venetoclax with other treatments may improve survival and quality of life for older adults with acute myeloid …
View Original Abstract ↓
Connective tissue disease (CTD) is one of the common autoimmune diseases (AIDs). Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disease characterized by peripheral blood monocytosis and bone marrow dysplasia, and it is frequently associated with autoimmune complications and secondary myelofibrosis (MF). This article reports a 52-year-old male patient with recurrent arthritis and fever as the main manifestations, for whom CTD was initially considered, and who received hormone and immunosuppressant combination therapy for 2 years 10 months. The patient still suffered from recurrent fever and severe anemia; further bone marrow cytology examinations revealed abnormal bone marrow hematopoiesis, and the final diagnosis was CTD complicated with CMML and MF (MF-3 grade). After the patient was transferred to the hematology department, we adopted the azacytidine + ruxolitinib dual-target regimen to simultaneously target autoimmune inflammation, malignant clonal hematopoiesis, and severe myelofibrosis. After treatment, the patient’s fever and other systemic symptoms were significantly relieved, monocytosis was corrected, and severe anemia and thrombocytopenia were markedly improved.
Budesonide-glycopyrronium-formoterol fumarate dihydrate improved lung function and reduced severe exacerbations versus budesonide-formoterol in inadequately controlled asthma
New Asthma Drug Cuts Attacks Without Recent Crisis
Related in Allergy & Immunology
FDA Approves Adrenalin (epinephrine) for Anaphylaxis and Septic Shock Hypotension
FDA approves Adrenalin for severe allergic reactions and septic shock.
The FDA approved Adrenalin (epinephrine) for emergency treatment of allergic reactions including anaphylaxis, and to increase mean arterial …
The FDA approved Adrenalin (epinephrine) to treat life-threatening allergic reactions and low blood pressure from septic shock. It is given …
Systemic Immune-Inflammation Index Shows Diagnostic and Prognostic Value in Thyroid Cancer
Immune Index Shows Link to Lymph Node Spread in Thyroid Cancer
A meta-analysis evaluated the Systemic Immune-Inflammation Index (SII) for diagnosing thyroid cancer and predicting lymph node metastasis. S…
A new analysis suggests that a specific immune marker could help doctors identify thyroid cancer and predict if it has spread to lymph nodes…
Small PNH clones in SLE linked to thrombotic events and hemolysis in case series
Small blood cell issues can impact patients with lupus and PNH
A systematic review of 8 cases found that 37.5% of SLE patients with PNH had thrombotic events and 87.5% had detectable hemolysis. The findi…
A review of cases shows that even small clusters of abnormal cells can cause serious blood complications in people with lupus and PNH.
Nanomedicine delivery systems may enhance immunotherapy efficacy in colorectal cancer
Nanomedicine may boost immunotherapy for colorectal cancer
This systematic review explores how nanomedicine delivery systems (liposomes, polymeric nanoparticles, metal nanoparticles) can remodel the …
Tiny particles could help immune therapies work better against colorectal cancer by changing the tumor environment.
From Other Specialties
Multidisciplinary analysis identifies systemic barriers and age-responsive care needs for older adults living with HIV
Older adults with HIV face unique barriers to consistent care
This narrative review uses an ecological framework to analyze the multidimensional challenges faced by older adults living with HIV in the P…
Older people living with HIV in the Philippines face a mix of ageism, health literacy gaps, and system failures that make getting care harde…
State-aware approaches improve interpretation of gene-environment interactions by focusing on biological states over exposures
New approach improves how we understand gene and environment interactions
This mini-review discusses the conceptual framework of gene-environment (G x E) interactions in genetic epidemiology. The authors argue that…
Researchers propose a new way to interpret how our genes interact with the environment by focusing on biological states rather than just ext…
Alginate oligosaccharides function as potential modulators for sodium reduction in coated and fried food systems
New ways to reduce salt in fried and coated foods
This systematic review synthesizes peer-reviewed literature from 2005 to 2025 regarding the role of alginate-derived hydrocolloids in sodium…
Special fibers could help keep fried foods like chicken nuggets tasty even when the amount of salt is lowered.
Dupilumab as an off-label adjunctive approach facilitates corticosteroid minimization in severe pemphigus vulgaris
New approach helps manage severe skin disease with fewer steroids
This case report describes the use of dupilumab as an off-label adjunctive corticosteroid-minimizing approach for a patient with severe muco…
A new way to treat a severe blistering skin disease may help patients who cannot safely take high doses of steroids.